Inventiva's Half-Year Liquidity Contract Review with Kepler Cheuvreux

Inventiva, a company focused on developing therapies for metabolic liver diseases, has released a half-year review of its liquidity contract with Kepler Cheuvreux. As of June 30, 2025, Inventiva's liquidity account held €428,212.57 in cash and 84,532 shares. There were 1,642 buy-side executions totaling 267,584 shares for €744,692.94, and 1,878 sell-side executions totaling 296,504 shares for €819,771.51.

Comparatively, at the end of 2024, Inventiva's account had €349,630.55 in cash and 113,452 shares, with less activity observed on both buy and sell sides. The liquidity contract aims to stabilize the company's stock performance on the market.

Inventiva continues to progress in its clinical trials, focusing on treatments for non-alcoholic steatohepatitis, aiming to address significant unmet medical needs.